Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate

By Wong D.T.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 10, 1998-10 ,pp. : 1691-1699

Informa Healthcare

Access to resources Recommend Favorite

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†

By  

Human Psychopharmacology: Clinical And Experimental (Electronic), Vol. 30, Iss. 4, 2015-07 ,pp. : 327-327

John Wiley & Sons Inc

Access to resources Recommend Favorite

Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

By Silver Henry  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2053-2058

Informa Healthcare

Access to resources Recommend Favorite

Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder

By Dell’Osso Bernardo   Allen Andrea   Hollander Eric  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 15, 2005-12 ,pp. : 2727-2740

Informa Healthcare

Access to resources Recommend Favorite

Duloxetine: In Stress Urinary Incontinence

By Paul L. McCormack   Gillian M. Keating  

Drugs, Vol. 64, Iss. 22, 2004-01 ,pp. : 2567-2573

Adis International

Access to resources Recommend Favorite